CME/CE Test

SGLT2 inhibitors were initially approved by the FDA for the treatment of hyperglycemia in patients with type 2 diabetes based on efficacy data from large, randomized outcomes trials.

How can the most common adverse event with SGLT2 inhibitors be managed?

Drink cranberry juice

Take prophylactic antibiotics

Use topical antifungal medications

Dedicated renal outcomes trials of SGLT2 inhibitors in patients with CKD with or without diabetes has shown what consistent result?

No effect on heart failure

Slowing of age-related decline in GFR

SGLT2 inhibitors should not be used below eGFR of 45 mg/min/1.73m²

Finerenone, the only FDA-approved nonsteroidal MRA for CKD in type 2 diabetes, showed what effect on CV events in clinical trials?

Increased CV events

No effect on CV events

Reduced CV events

While the risk of hyperkalemia is less with nonsteroidal MRAs than with steroidal MRAs, serum potassium still needs to be measured and monitored.

The dose of finerenone should be withheld when serum potassium reaches what level?

Greater than 4.8 mmol/L

Greater than 5.5 mmol/L

Greater than 6.5 mmol/L

CME/CE Test

Updates on Clinical Use of Non-Steroidal Mineralocorticoid Receptor Antagonists in the Management of Chronic Kidney Disease in Patients With Type 2 Diabetes